Kit for detecting mycoplasma pneumonia

Abstract

The invention relates to a kit for detecting mycoplasma pneumonia. The kit comprises an R1 reagent and an R2 reagent. The R1 reagent comprises a first buffer, a first stabilizer, a first protectant, afirst preservative, an opacifier and water. The R2 reagent comprises mycoplasma pneumonia antigens, polystyrene latex microspheres, a second buffer, a second stabilizer, a second protectant, a secondpreservative and water. The kit of the invention has the advantages of high sensitivity, high detection speed, stable result, wide linear range, good repetition, easy to standardize and specimen collection, and small in specimen usage amount and the like. Also, the kit of the invention has the advantages that it provides a novel method for early, rapid, high sensitivity and specificity for the diagnosis of clinical mycoplasma pneumonia infection.

Description

technical field [0001] The invention relates to the field of in vitro diagnostic reagents, in particular to a kit for detecting mycoplasma pneumoniae. Background technique [0002] Mycoplasma pneumoniae (Mycoplasma pneumoniae, MP) is one of the important pathogens of children's community-acquired pneumonia. MP infection accounts for 10%-30% of children's community-acquired pneumonia infection, and it mostly occurs in families, communities, schools and camping areas. crowded public places. MP infection is seasonal, mostly occurs in autumn, and is mainly transmitted by droplets. Most MP infections are limited. Whether clinical infection symptoms appear depends on whether MP adhered to the surface of the host’s respiratory tract can be cleared, but there are still 3%- 13% cause clinical symptoms, the main symptom is dry cough, body temperature at 37.7±1.0°C, and last for 1-3 weeks, may be accompanied by sore throat and muscle pain, lack of specific clinical features, and appro...

AI Technical Summary

Problems solved by technology

The isolation and culture method is the gold standard for diagnosing MP infection, but it requires high culture conditions and a long culture period (10-14 days). It is generally used for scientific research and clinical retrospective analysis, and has little significance for the early diagnosis of MP. It is rarely used now. Clinical diagnosis; molecular biology including: nested PCR, real-time quantitative PCR, loop-mediated isothermal amplification reaction (LAMP) technology, nucleic acid sequence-dependent amplification technology (NASBA), real-time fluorescent nucleic acid constant temperature amplification detection technology (SAT) Composite PCR and other technologies, molecular biology techniques have high sensitivity and specificity, and are suitable for early clinical diagnosis. However, in addition to the shortcomings of molecular biology itself, such as high false positive rate and easy contamination of specimens, studies have found that MP in healthy people The carrier rate is high (0.1%-13.5%), and the DNA can survive in the respiratory tract for a long time after infection (7 weeks to 7 months). Combined with c

Images